FDA Approves New Bladder Cancer Treatment for Patients

Bladder cancer patients who ran out of treatment options just got new hope from the FDA.

The agency recently expanded approval of Anktiva, an immunotherapy treatment, for adults with high-grade bladder cancer that didn't respond to the standard BCG therapy. For these patients, watching their cancer return despite treatment meant facing tough choices, including potentially losing their bladder entirely.

Anktiva works differently than traditional treatments. Instead of attacking cancer cells directly, it supercharges the body's own immune system by activating natural killer cells and T cells that recognize and destroy abnormal cells.

The treatment gets delivered directly into the bladder through a catheter, starting with weekly doses for six weeks. Depending on how patients respond, treatment can continue for up to 37 months, giving the immune system sustained support in fighting cancer.

The FDA first approved Anktiva in April 2024 for one type of bladder cancer. The latest expansion covers patients with high-grade papillary-only disease, a group that previously had fewer bladder-preserving options when standard immunotherapy failed.

The Bright Side

The approval came faster than usual because researchers discovered that different types of high-grade bladder cancer share key biological features. This scientific similarity allowed the FDA to apply existing evidence to help more patients sooner.

In clinical trials, 62% of patients showed no detectable high-grade cancer during assessments. Even better, more than half of those who responded stayed cancer-free for at least a year, and 40% maintained their response for two years or longer.

Dr. Angelo de Claro, director of the FDA's Oncology Center of Excellence, emphasized the agency's commitment to listening to patients and acting when science supports new approaches. This decision may also guide how future bladder cancer treatments get developed and approved.

For patients facing BCG-unresponsive bladder cancer, this approval means more than just another treatment option. It represents a chance to keep their bladder, maintain their quality of life, and give their immune system powerful new tools in the fight against cancer.